藥明巨諾-B(02126.HK)與賽默飛達成戰略合作 聯手發力細胞治療的應用及商業化生產
格隆匯 2 月 3日丨藥明巨諾-B(02126.HK)宣佈，藥明巨諾與賽默飛世爾科技("賽默飛")達成了一項戰略合作協議("CAR-T合作協")，以聯手發力細胞治療的應用及商業化生產。根據CAR-T合作協議條款，藥明巨諾將獲得賽默飛Gibco™ CTS™Dynabeads™ CD3/CD28磁珠的非排他性商業化使用權利。
CAR-T合作協議將進一步推動藥明巨諾的主打產品瑞基奧侖賽注射液(“”relma-cel“”)等領先CAR-T療法(嵌合抗原受體T細胞免疫療法)在中國的臨牀開發及商業化生產。Relma-cel是抗CD19的CAR-T療法，用於三線治療復發或難治性("r/r")B細胞淋巴瘤患者，其新藥上市申請已被中國國家藥品監督管理局受理，有望成為中國首個獲批的一類生物製品的CAR-T療法。
CTS Dynabeads磁珠是賽默飛經過驗證的CTS(細胞治療系統)系列產品之一，有助於優化已獲批T細胞療法從臨牀研究到商業化生產的過程。CTS產品線整合了從細胞分離與激活、基因轉導，到細胞擴增全流程的產品解決方案，有助於細胞治療開發者解決在生產工藝中所面臨的挑戰。賽默飛CTS Dynabeads磁珠技術提供了一個可擴展的平台，用於優化細胞治療的研發和生產過程，同時確保其結果的高可重複性。
賽默飛執行副總裁兼首席運營官施傑奕(Mark Stevenson)表示，"隨着藥明巨諾Relma-cel的新藥上市申請被正式受理，其商業化進程正逐漸加速，賽默飛將與藥明巨諾並肩合作，儘快推動該產品規模化商業生產落地。賽默飛始終秉持‘紮根中國，服務中國’的理念，確保為合作伙伴實現精準醫療規模化生產提供穩定的供應與領先的技術支持。“
”藥明巨諾執行副總裁兼首席技術官林立源(Harry Lam)博士表示：“”此次戰略合作會進一步鞏固雙方的合作伙伴關係。隨着藥明巨諾即將在商業化佈局上迎來重要里程碑，與賽默飛的合作將確保我們擁有充足的資源供應，以擴大產業化規模，更好地服務於中國患者未被滿足的醫療需求。"
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
